Research programme: megakaryocyte progenitor cell therapeutics - Cellerant Therapeutics

Drug Profile

Research programme: megakaryocyte progenitor cell therapeutics - Cellerant Therapeutics

Alternative Names: CLT-009 - Cellerant Therapeutics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellerant Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Acute radiation syndrome
  • No development reported Thrombocytopenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in USA (Parenteral)
  • 11 Sep 2014 Preclinical trials in Acute radiation syndrome in USA (Parenteral)
  • 10 Oct 2012 Cellerant Therapeutics receives a Small Business Innovation Research phase I and phase II option grant from the National Cancer Institute to develop CLT 009 for Thrombocytopenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top